ASTRAZENECA PLC

AstraZeneca PLC operates within the pharmaceutical sector, focusing on the development and commercialization of innovative medicines. The company's business model is centered on generating revenue through product sales and collaboration agreements across various therapy areas, including Oncology, Cardiovascular, Renal & Metabolism (CVRM), Respiratory & Immunology, Vaccines & Immune Therapies, and Rare Disease. The company maintains an active presence in over 80 countries, with significant operations in the US, Emerging Markets (including China), Europe, and Established Rest of World (ROW) regions. Revenue streams include both direct product sales and alliance/collaboration revenues, reflecting a mix of transactional and recurring income from partnerships.

The company's core business model involves extensive research and development to discover and advance new molecular entities and significant indications through clinical trials. Successful development leads to regulatory approvals and subsequent commercialization. Revenue is generated from the sale of these approved pharmaceutical products to various customer segments, including healthcare providers, managed care organizations, and government programs. The company also engages in licensing arrangements and strategic collaborations to expand its portfolio, which often involve milestone payments and shared commercialization efforts.

In the Oncology segment, key products include Tagrisso, a selective EGFR-TKI for early- and late-stage EGFRm NSCLC, which generated $3,064 million ⁴ in US sales and $1,971 million ⁵ in Emerging Markets sales in 2025. Imfinzi, a PD-L1 mAb, recorded US sales of $3,509 million ⁶ and Emerging Markets sales of $640 million ⁷. Calquence, a BTK inhibitor, achieved US sales of $2,339 million ⁸ and Emerging Markets sales of $233 million ⁹. Lynparza, a PARP inhibitor, contributed $1,434 million ¹⁰ in US sales and $669 million ¹¹ in Emerging Markets sales. Enhertu, a HER2-directed ADC, generated $977 million ¹² in total product sales, with $668 million ¹³ from Emerging Markets. Truqap, an AKT inhibitor, had US sales of $586 million ¹⁴. Datroway, a TROP2-directed ADC, recorded $2 million ¹⁵ in total product sales.

The Cardiovascular, Renal & Metabolism (CVRM) segment features Farxiga/Forxiga, an SGLT-2 inhibitor, with US sales of $1,730 million ¹⁶ and Emerging Markets sales of $3,324 million ¹⁷. Brilinta/Brilique, an oral P2Y12 platelet inhibitor, generated US sales of $393 million ¹⁸. Lokelma, a potassium-removing agent, recorded US sales of $301 million ¹⁹ and Emerging Markets sales of $129 million ²⁰. Wainua, a ligand-conjugated antisense, achieved US sales of $204 million ²¹.

In the Respiratory & Immunology segment, Symbicort, a combination ICS/LABA, had US sales of $1,193 million ²² and Emerging Markets sales of $801 million ²³. Fasenra, an IL-5R mAb, generated US sales of $1,195 million ²⁴ and Europe sales of $482 million ²⁵. Breztri/Trixeo Aerosphere, a triple combination therapy, recorded US sales of $614 million ²⁶ and Emerging Markets sales of $298 million ²⁷. Saphnelo, a type I IFN receptor mAb, achieved US sales of $596 million ²⁸ and Europe sales of $49 million ²⁹. Tezspire, a TSLP mAb, generated $458 million ³⁰ in total product sales, with $297 million ³¹ from Europe. Airsupra, a fixed-dose combination rescue medication for asthma, had US sales of $162 million ³².

The Vaccines & Immune Therapies segment includes Beyfortus, a long-acting anti-RSV F mAb, with US sales of $184 million ³³ and Europe sales of $94 million ³⁴. FluMist, a live attenuated influenza vaccine, generated US sales of $28 million ³⁵. The Rare Disease segment includes Ultomiris, a C5 complement inhibitor, with US sales of $2,667 million ³⁶ and Europe sales of $1,053 million ³⁷. Soliris, also a C5 complement inhibitor, recorded US sales of $1,092 million ³⁸ and Europe sales of $200 million ³⁹. Strensiq, an enzyme replacement therapy, achieved US sales of $1,332 million ⁴⁰ and Emerging Markets sales of $104 million ⁴¹. Koselugo, a MEK inhibitor, generated US sales of $219 million ⁴² and Emerging Markets sales of $228 million ⁴³.

For the fiscal year ended December 31, 2025, total Product Sales increased by 9% (9% at Constant Exchange Rate, CER) to $55,573 million ⁴⁴ from $50,938 million ⁴⁵ in 2024 and $43,789 million ⁴⁶ in 2023. Gross profit is not explicitly stated as a single figure for the entire company, but rather as a component of core gross profit. Operating income is not explicitly stated as a single figure for the entire company. Net income is not explicitly stated as a single figure for the entire company. Diluted EPS is not explicitly stated as a single figure for the entire company. Cash and cash equivalents are not explicitly stated as a single figure for the entire company. Total debt is not explicitly stated as a single figure for the entire company.

Year-over-year, Product Sales in the US increased by 8% to $23,444 million ⁴⁷ in 2025, following a 21% increase in 2024 to $21,655 million ⁴⁸. Emerging Markets Product Sales increased by 11% (CER: 13%) to $15,056 million ⁴⁹ in 2025, after a 15% (CER: 23%) increase in 2024 to $13,535 million ⁵⁰. Europe Product Sales increased by 11% (CER: 7%) to $12,021 million ⁵¹ in 2025, following a 20% (CER: 19%) increase in 2024 to $10,848 million ⁵². Established ROW Product Sales increased by 3% (CER: 3%) to $5,052 million ⁵³ in 2025, after a 3% decrease (CER: 3% increase) in 2024 to $4,900 million ⁵⁴. Notable shifts include the significant growth of Enhertu in Emerging Markets (91% actual, 95% CER) and Truqap in the US (44% actual), while Brilinta in the US saw a 48% decrease due to generic entry.

During 2025, AstraZeneca saw the rapid adoption of Enhertu in HER2-positive and HER2-low breast cancer in Emerging Markets following NRDL enlistment from January 1, 2025. Truqap achieved a rapidly reached peak share in second-line biomarker-altered metastatic breast cancer in the US. Airsupra demonstrated strong launch momentum and volume uptake in the US. In the Rare Disease segment, Ultomiris continued to see demand growth across indications, while Soliris sales decreased due to conversion to Ultomiris and biosimilar competition. The company also noted the impact of generic entry for Brilinta in the US and Forxiga in the UK.

The filing does not provide specific revenue, margin, or EPS guidance for the upcoming period.

A key growth area for AstraZeneca is the continued expansion of its Oncology portfolio. Enhertu, a HER2-directed ADC, is expected to drive growth with ongoing launches and expanded indications. For instance, Enhertu is in Phase III trials for 1L HER2+ biliary tract cancer in combination with rilvegostomig, and for 1L HER2+ pMMR endometrial cancer in combination with rilvegostomig/pembrolizumab, with data readouts anticipated beyond 2027. The product is also in Phase III for 1L HER2m NSCLC with a data readout expected in H1 2026. Datroway, a TROP2-directed ADC, is another significant growth driver, with Phase III trials for 1L TNBC not candidates for IO, which has been accepted, and for 1L EGFRm NSCLC in combination with Tagrisso, with a data readout beyond 2027. The company is also advancing saruparib, a PARP1 inhibitor, in various prostate and breast cancer indications, with data readouts expected beyond 2027.

In the CVRM segment, Wainua, a ligand-conjugated antisense, is anticipated to expand its market with a Phase III trial for hereditary or wild-type transthyretin-mediated amyloid cardiomyopathy (ATTR CM), with a data readout expected in H2 2026. Baxdrostat, an aldosterone synthase inhibitor, is in Phase III for hypertension, with its submission status accepted, and for primary aldosteronism, with a data readout beyond 2027. These developments aim to address significant unmet medical needs and contribute to future revenue growth.

The filing does not explicitly detail the margin trajectory, cost structure evolution, or efficiency/restructuring targets with exact figures for the upcoming period.

The filing does not explicitly detail the supply chain posture, manufacturing capacity, technology infrastructure investments, or headcount/workforce strategy for the upcoming period.

The filing does not provide specific planned capital allocation figures for R&D spending levels, capital expenditure plans, share repurchase authorization amounts, or dividend policy for the upcoming period.

Management has explicitly flagged several structural headwinds and execution risks to the growth plan. These include product pipeline risks such as failure or delay in the delivery of the pipeline or launch of new medicines, and failure to meet regulatory or ethical requirements for medicine development or approval. Commercialization risks encompass pricing, affordability, access, and competitive pressures, as well as failures or delays in the quality or execution of the Group’s commercial strategies, particularly in emerging markets. Supply chain and business execution risks include failure to maintain supply of compliant, quality medicines, failure in information technology or cybersecurity, failure to collect and manage data and AI in line with legal and regulatory requirements and strategic objectives, illegal trade in the Group’s medicines, reliance on third-party goods and services, and failure of critical processes. Legal, regulatory, and compliance risks involve questions regarding the safety and efficacy of marketed medicines, adverse outcomes of litigation and/or governmental investigations, IP risks related to products, failure to meet sustainability targets and regulatory requirements with respect to the environment, and failure to meet regulatory and ethical expectations on commercial practices. Economic and financial risks include geopolitical and/or macroeconomic volatility disrupting global business operations, failure to achieve strategic plans or meet targets or expectations, failure in internal control, financial reporting or the occurrence of fraud, and unexpected deterioration in the Group’s financial position due to exchange rate movements, investment impairments, and defined benefit post-retirement obligations.

AstraZeneca faces material risks across several categories. Product pipeline risks include the potential for failure or delay in the delivery of new medicines due to unfavorable clinical efficacy data, safety concerns, or regulatory demands, which could damage R&D reputation and adversely affect future business and results of operations. Commercialization risks are significant, stemming from increasing cost-containment measures globally, dynamic economic, political, and social pressures on pricing, and policy changes like the EU Joint Clinical Assessment and the US Inflation Reduction Act. Failure to execute commercial strategies, especially in emerging markets with volatile climates and inadequate protection against crime, could materially impact sales. Supply chain and business execution risks involve potential disruptions from natural disasters, climate impacts, pandemics, conflict, or IT failures (including cyber-attacks), leading to product shortages and reputational damage. The company also faces risks related to data and AI management, including non-compliance with privacy and AI regulations, which could result in material regulatory sanctions or fines. Legal and regulatory risks are inherent, with potential for large product liability claims from unforeseen safety concerns, adverse outcomes from litigation and governmental investigations (e.g., anti-bribery/anti-corruption, anti-fraud), and challenges to intellectual property rights, which could lead to loss of patent protection and revenue. Economic and financial risks include geopolitical and macroeconomic volatility, such as sustained global economic downturns, high inflation, and large fluctuations in exchange rates, which can adversely impact financial markets and pressure medicine prices. The company's financial position is also exposed to movements in exchange rates against the US dollar, with key currencies being the euro, Chinese renminbi, pound sterling, Japanese yen, and Swedish krona. Investments in intangible assets carry impairment risk, and defined benefit post-retirement obligations could require higher cash contributions if asset values fall or liability valuations increase.

Management's message to shareholders emphasizes a strong commercial performance across all therapy areas, with Product Sales increasing by 9% (CER: 9%) to $55,573 million ⁴⁴ in 2025. The company highlights continued growth in Oncology medicines, Ultomiris, and Saphnelo in the US, alongside significant growth in Emerging Markets driven by Oncology and CVRM medicines. Key strategic priorities include maximizing the commercial potential of new products, expanding the portfolio through internal development and strategic collaborations, and maintaining a robust pipeline. Management also stresses the importance of balancing pricing with patient access, value, sustainability, and equity across the more than 80 countries where AstraZeneca operates. The company is actively investing in AI experimentation, development, and deployment to accelerate drug discovery, optimize manufacturing, and drive efficiencies, while also acknowledging the associated risks.